SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation

The RET receptor tyrosine kinase proto-oncogene is activated by somatic or germline mutations in a majority of medullary thyroid cancers (MTC). However, treatment of MTC has been challenging due to the lack of effective and tolerable RET-specific therapy, thus testing tumors for the presence of soma...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Cabanillas, Maria E, Wirth, Lori J, Sherman, Eric J, Drilon, Alexander, Solomon, Benjamin, Robinson, Bruce G, Lorch, Jochen H, McCoach, Caroline, Patel, Jyoti, Leboulleux, Sophie, Worden, Francis, Owonikoko, Taofeek K, Brose, Marcia S, Taylor, Matthew H, Subbiah, Vivek, Rothenberg, S Michael, Huang, Xin, Zhu, Edward, French, Pearl P, Shah, Manisha H
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Thyroid
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7208240/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.2223
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados